JY
VERA icon

Jeff Yass’s Vera Therapeutics VERA Stock Holding History

Jeff Yass’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.15M Sell
73,400
-87,400
-54% -$3.26M ﹤0.01% 5527
2026
Q1 		$6.47M Buy
160,800
+99,200
+161% +$4.27M ﹤0.01% 3811
2025
Q4 		$3.12M Sell
61,600
-4,900
-7% -$174K ﹤0.01% 4810
2025
Q3 		$1.93M Sell
66,500
-328,500
-83% -$7.6M ﹤0.01% 5863
2025
Q2 		$9.31M Buy
395,000
+117,000
+42% +$2.63M ﹤0.01% 2929
2025
Q1 		$6.68M Buy
278,000
+254,000
+1,058% +$8.16M ﹤0.01% 3130
2024
Q4 		$1.01M Sell
24,000
-71,000
-75% -$3.14M ﹤0.01% 6908
2024
Q3 		$4.2M Buy
95,000
+55,200
+139% +$2.09M ﹤0.01% 3903
2024
Q2 		$1.44M Sell
39,800
-47,200
-54% -$1.87M ﹤0.01% 5758
2024
Q1 		$3.75M Buy
+87,000
New +$3.1M ﹤0.01% 4118
2023
Q4 		– Sell
-11,400
Closed -$156K – 13362
2023
Q3 		$156K Sell
11,400
-41,200
-78% -$707K ﹤0.01% 10508
2023
Q2 		$844K Buy
52,600
+34,700
+194% +$313K ﹤0.01% 7080
2023
Q1 		$139K Buy
+17,900
New +$138K ﹤0.01% 10988

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jeff Yass's VERA Position: Q2 2026 in Review

Jeff Yass increased its Vera Therapeutics (VERA) stake by 33% in Q2 2026, buying an estimated $1.48M and bringing the position to 160,837 shares worth $6.9M. The position accounts for ﹤0.01% of the portfolio, ranked #4022.

Jeff Yass first reported a position in VERA in Q1 2023 and has held it in 14 quarters since. The position peaked at $8.95M in Q4 2025. 218 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Jeff Yass held 160,837 shares of Vera Therapeutics worth $6.9M as of Q2 2026.
  • Jeff Yass bought 39,817 Vera Therapeutics shares in Q2 2026, an estimated $1.48M.
  • Vera Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #4022 holding.
  • Jeff Yass first reported a position in Vera Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Jeff Yass's Vera Therapeutics position peaked at $8.95M in Q4 2025.
  • 218 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.